Benzyl imidazol-1-ylacetate | 134807-23-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Benzyl imidazol-1-ylacetate
• 英文别名: Benzyl 2-(1-Imidazolyl)acetate；benzyl 1-imidazolylacetate；imidazol-1-yl-acetic acid benzyl ester；1H-Imidazole-1-acetic acid, phenylmethyl ester；benzyl 2-imidazol-1-ylacetate
• CAS: 134807-23-1
• 化学式: C₁₂H₁₂N₂O₂
• 分子量: 216.239
• InChiKey: MDPKYAPCYDAGSN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Benzyl imidazol-1-ylacetate 在 臭氧 作用下， 以 甲醇 为溶剂， 以71%的产率得到N-<(benzyloxycarbonyl)methyl>-N-formylformamide
  参考文献：
  名称：

  Ozonolysis of 1-Substituted Imidazoles

  摘要：

  1-Substituted imidazoles was ozonolyzed cleanly without any complicated procedures into the corresponding N-acylamides, which were regarded to be much useful derivatives of either amines or acyl compounds.

  DOI：

  10.3987/com-91-s67
• 作为产物：
  描述：

  咪唑 、 2-溴乙酸苄酯 在 1,5-bis<(N-benzyl-N,N-diethylammonio)ethyl> ether dichloride 氢氧化钾 、 potassium carbonate 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 以51%的产率得到Benzyl imidazol-1-ylacetate
  参考文献：
  名称：

  Synthesis and Regioselective Hydrolysis of 2-(Imidazol-1-yl)succinic Esters

  摘要：

  (±)-2-咪唑-1-基琥珀酸酯是通过将咪唑与富马酸酯或马来酸酯在热条件下进行加成反应而合成的。在某些情况下，通过微波加热可以加速反应进程。这些酯在中性条件下经历一种简单的区域选择性水解，生成相应的半酯：(±)-3-(烷氧基羰基)-2-咪唑-1-基丙二酸，其水解机制可能涉及BAC(3)或BAL(1)路径。在H2O和D2O中的动力学研究，以及O-18和O-17的标记实验结果，均支持了所提出的水解机制。这些水解产物的性质依赖于醇基的类型，与一些咪唑-1-基丙二酸酯类似物，或与(±)-2-吡唑-1-基和苯并咪唑-1-基琥珀酸酯的水解结果进行比较。总体而言，咪唑基琥珀酸酯的水解速度比来自吡唑或苯并咪唑的同类衍生物更快。

  DOI：

  10.1021/jo00100a030

文献信息

• [EN] A PROCESS FOR THE PREPARATION OF 2-(IMIDAZOL-1-YL)-1-HYDROXYETHANE-1, 1-DIPHOSPHONIC ACID<br/>[FR] PROCEDE DE PREPARATION D'ACIDE 2-(IMIDAZOL-1-YL)-1-HYDROXYETHANE-1,1-DIPHOSPHONIQUE
  申请人：SUN PHARMACEUTICAL IND LTD

  公开号：WO2005066188A1

  公开（公告）日：2005-07-21

  The present invention provides a process for preparation of 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid, compound of formula (1), said process comprising (a) reacting imidazole with chloroacetyl chloride and benzyl alcohol in homogenous system in one pot to obtain benzyl 1-imidazolylacetate, compound of formula (3); (b) debenzylating benzyl 1-imidazolylacetate, a compound of formula (3) to imidazole 1-ylacetic acid, compound of formula (2) and (c) converting compound of formula (2) to compound of formula (1).

  本发明提供了一种制备2-(咪唑-1-基)-1-羟基乙烷-1,1-二膦酸的方法，该化合物的化学式为(1)，该方法包括(a)在均相体系中将咪唑与氯乙酰氯和苄醇在一个锅中反应，以获得苄基-1-咪唑基乙酸酯，化合物的化学式为(3)；(b)对苄基-1-咪唑基乙酸酯进行脱苄基处理，得到咪唑-1-基乙酸，化合物的化学式为(2)；(c)将化合物的化学式(2)转化为化合物的化学式(1)。
• Synthesis of a series of amino acid derived ionic liquids and tertiary amines: green chemistry metrics including microbial toxicity and preliminary biodegradation data analysis
  作者：Andrew Jordan、Annette Haiß、Marcel Spulak、Yevgen Karpichev、Klaus Kümmerer、Nicholas Gathergood

  DOI：10.1039/c6gc00415f

  日期：——

  A series ofl-phenylalanine andl-tyrosine derived ionic liquids and tertiary amines were evaluated according to principles of green chemistry.

  一系列由L-苯丙氨酸和L-酪氨酸衍生的离子液体和三级胺根据绿色化学原则进行评估。
• Retroviral protease inhibiting compounds
  申请人：Abbott Laboratories

  公开号：US05142056A1

  公开（公告）日：1992-08-25

  A retroviral protease inhibiting compound of the formula A--X--B or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein X is a linking group; A is (1) substituted amino, (2) substituted carbonyl, (3) functionalized imino, (4) functionalized alkyl, (5) functionalized acyl, (6) functionalized heterocyclic or (7) functionalized (heterocyclic)alkyl; and B is (1) substituted carbonyl independently defined as herein, (2) substituted amino independently defined as herein, (3) functionalized imino independently defined as herein, (4) functionalized alkyl independently defined as herein, (5) functionalized acyl independently defined as herein, (6) functionalized heterocyclic independently defined as herein or (7) functionalized (heterocyclic)alkyl independently defined as herein.

  一种抑制逆转录病毒蛋白酶的化合物，其化学式为A--X--B或其药用盐、前药或酯，其中X为连接基；A为（1）取代氨基，（2）取代羰基，（3）官能化亚胺基，（4）官能化烷基，（5）官能化酰基，（6）官能化杂环基或（7）官能化（杂环）烷基；B为（1）取代羰基，独立定义如本文所述，（2）取代氨基，独立定义如本文所述，（3）官能化亚胺基，独立定义如本文所述，（4）官能化烷基，独立定义如本文所述，（5）官能化酰基，独立定义如本文所述，（6）官能化杂环基，独立定义如本文所述或（7）官能化（杂环）烷基，独立定义如本文所述。
• Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System
  申请人：Gupta Ajay

  公开号：US20110319459A1

  公开（公告）日：2011-12-29

  Disclosed are compounds of the general formula (I): TC n D  (I), compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.

  本发明涉及一般式（I）的化合物：TCnD（I），包括单独使用或与其他化疗药物联合使用的有效量的该化合物的组合物，以及用于治疗或预防癌症和抑制肿瘤组织生长的有用方法。这些化合物减弱了与增加血红素氧合酶活性相关的氧化损伤，并可以减少转化细胞中的细胞增殖。此外，所述化合物和组合物可用作神经保护剂，并用于治疗或预防中枢神经系统的神经退行性疾病和其他疾病。
• Intermediates for preparating non-peptide retroviral protease inhibitors
  申请人：ABBOTT LABORATORIES

  公开号：EP0839798A2

  公开（公告）日：1998-05-06

  Intermediates, for preparing non-peptide retroviral protease inhibitors, said intermediates having the formula: or an acid addition salt thereof or an N-protected derivative thereof wherein at each occurrence the N-protecting group is independently selected from the group consisting of formyl, acetyl, pivaloyl, t-butylacetyl, t-butyloxycarbonyl, benzyloxycarbonyl, benzyl and isopropylaminocarbonyl; or said intermediates being selected from: (2S,3R,4S,5S)-2,5-di-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3S,4S,5S)-2,5-di-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3R,4R,5S)-2,5-di-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3S,4S,5S)-2,5-di-(N-(valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3R,4S,5S)-2,5-di-(N-(valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3R,4R,5S)-2,5-di-(N-(valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3S,4R,5S)-2-(N-(t-butyloxy)carbonyl)amino)-5-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; 2-(N-benzyl-N-(benzyloxycarbonyl)amino)-5-(t-butyloxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide; 2-amino-5-(t-butyloxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide; and 2,5-di-(t-butyloxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide; or an acid addition salt thereof.

  用于制备非肽类逆转录病毒蛋白酶抑制剂的中间体，所述中间体具有以下式子： 或其酸加成盐或其 N-保护衍生物，其中每次出现时，N-保护基独立选自甲酰、乙酰、特戊酰、叔丁基乙酰、叔丁氧羰基、苄氧羰基、苄基和异丙氨基羰基组成的组；或所述中间体选自以下物质 (2S,3R,4S,5S)-2,5-二(N-(Cbz-缬氨酰)氨基)-3,4-二羟基-1,6-二苯基己烷； (2S,3S,4S,5S)-2,5-二(N-苄氧羰基缬氨酰氨基)-3,4-二羟基-1,6-二苯基己烷； (2S,3R,4R,5S)-2,5-二(N-苄氧羰基缬氨酰氨基)-3,4-二羟基-1,6-二苯基己烷； (2S,3S,4S,5S)-2,5-二(N-(缬氨酰)氨基)-3,4-二羟基-1,6-二苯基己烷； (2S,3R,4S,5S)-2,5-二(N-(缬氨酰)氨基)-3,4-二羟基-1,6-二苯基己烷； (2S,3R,4R,5S)-2,5-二(N-(缬氨酰)氨基)-3,4-二羟基-1,6-二苯基己烷； (2S,3S,4R,5S)-2-(N-(叔丁氧基)羰基)氨基)-5-(N-(Cbz-缬氨酰)氨基)-3,4-二羟基-1,6-二苯基己烷； 2-(N-苄基-N-(苄氧羰基)氨基)-5-(叔丁氧羰基氨基)-1,6-二苯基-3-己烯-3,4-氧化物； 2-氨基-5-(叔丁氧羰基氨基)-1,6-二苯基-3-己烯-3,4-氧化物；以及 2,5-二（叔丁氧羰基氨基）-1,6-二苯基-3-己烯-3,4-氧化物； 或其酸加成盐。